Standards Comparison

    GMP

    Mandatory
    1963

    Global standards ensuring pharmaceutical manufacturing quality control

    VS

    EU AI Act

    Mandatory
    2024

    EU regulation for risk-based AI safety and governance

    Quick Verdict

    GMP ensures consistent manufacturing quality in pharma via preventive controls and validation, while EU AI Act regulates high-risk AI systems with conformity assessments and risk management. Companies adopt GMP for patient safety and market access; AI Act for legal compliance and trust.

    Manufacturing Quality

    GMP

    Good Manufacturing Practice (GMP)

    Cost
    €€€
    Complexity
    Medium
    Implementation Time
    18-24 months

    Key Features

    • Mandates independent quality unit batch release authority
    • Requires validated processes preventing contamination and mix-ups
    • Enforces risk-based Quality Risk Management proportionality
    • Demands comprehensive documentation ensuring traceability and integrity
    • Establishes facility controls for environmental contamination prevention
    Artificial Intelligence

    EU AI Act

    Regulation (EU) 2024/1689 Artificial Intelligence Act

    Cost
    €€€
    Complexity
    Medium
    Implementation Time
    18-24 months

    Key Features

    • Risk-based classification into four tiers
    • Prohibited unacceptable-risk AI practices
    • High-risk conformity assessment and CE marking
    • GPAI systemic risk evaluations and reporting
    • Lifecycle risk management and post-market monitoring

    Detailed Analysis

    A comprehensive look at the specific requirements, scope, and impact of each standard.

    GMP Details

    What It Is

    Good Manufacturing Practice (GMP) is a regulatory framework establishing minimum standards for manufacturing controls in pharmaceuticals, biologics, and related sectors. Its primary purpose is ensuring products are consistently produced to quality standards via preventive systems. Key approach is risk-based (QRM) with Pharmaceutical Quality System (PQS) lifecycle management, spanning materials to distribution.

    Key Components

    • Core pillars: 5 Ps (People, Premises, Processes, Procedures, Products)
    • Elements include validated processes, independent Quality Control Unit, documentation, training, facility controls, CAPA, change control
    • Built on ICH Q9/Q10, regional codes like FDA 21 CFR 211, EU EudraLex Volume 4
    • Compliance via inspections, no central certification but enforced regionally

    Why Organizations Use It

    Legal mandate protects patients, prevents recalls; reduces liability, ensures market access. Strategic benefits: supply reliability, efficiency, reputation. Builds stakeholder trust through proven state of control.

    Implementation Overview

    Phased: gap analysis, Validation Master Plan, qualification (IQ/OQ/PQ), training, audits. Applies to pharma manufacturers globally; high resource needs for facilities, systems.

    EU AI Act Details

    What It Is

    EU AI Act (Regulation (EU) 2024/1689) is a comprehensive EU regulation establishing the first horizontal framework for AI governance. It adopts a risk-based approach, prohibiting unacceptable-risk practices, regulating high-risk systems with lifecycle controls, imposing transparency on limited-risk AI, and minimally regulating others. Scope covers providers, deployers, and value-chain actors for AI systems used in the EU.

    Key Components

    • **Four risk tiersProhibited (Article 5), high-risk (Annexes I/III, Articles 6-15), limited-risk (transparency, Article 50), minimal-risk.
    • Core high-risk requirements: risk management (Article 9), data governance (Article 10), documentation (11-13), human oversight (14), cybersecurity (15).
    • GPAI obligations (Chapter V), conformity assessment, CE marking, EU database registration.
    • Built on product-safety principles; presumption of conformity via harmonized standards.

    Why Organizations Use It

    • Mandatory for EU market access, avoiding fines up to 7% global turnover.
    • Enhances risk management, trust, and competitiveness in sectors like employment, healthcare, law enforcement.
    • Builds stakeholder confidence through transparency and accountability.

    Implementation Overview

    • Phased: prohibitions (6 months), GPAI (12 months), high-risk (24-36 months post-1 Aug 2024).
    • Inventory AI assets, classify risks, build compliance systems, conduct assessments.
    • Applies to all sizes targeting EU; audits via notified bodies for high-risk.

    Key Differences

    Scope

    GMP
    Manufacturing controls for pharmaceuticals, biologics, APIs
    EU AI Act
    Risk-based AI systems lifecycle governance

    Industry

    GMP
    Pharma, biologics, medical devices, cosmetics, food
    EU AI Act
    All sectors using AI: finance, healthcare, employment, law enforcement

    Nature

    GMP
    Mandatory enforceable manufacturing standards
    EU AI Act
    Mandatory EU regulation with conformity assessments

    Testing

    GMP
    Process/equipment validation, IQ/OQ/PQ, audits
    EU AI Act
    Conformity assessments, notified bodies, post-market monitoring

    Penalties

    GMP
    Warning letters, recalls, import alerts
    EU AI Act
    Fines up to 7% global turnover, market bans

    Frequently Asked Questions

    Common questions about GMP and EU AI Act

    GMP FAQ

    EU AI Act FAQ

    You Might also be Interested in These Articles...

    Run Maturity Assessments with GRADUM

    Transform your compliance journey with our AI-powered assessment platform

    Assess your organization's maturity across multiple standards and regulations including ISO 27001, DORA, NIS2, NIST, GDPR, and hundreds more. Get actionable insights and track your progress with collaborative, AI-powered evaluations.

    100+ Standards & Regulations
    AI-Powered Insights
    Collaborative Assessments
    Actionable Recommendations

    Check out these other Gradum.io Standards Comparison Pages